Codebase Ventures Inc.: Codebase Receives Positive Technical Study Results for HCQ Transdermal Patch Technology
Codebase Ventures Inc.: Codebase Receives Positive Technical Study Results for HCQ Transdermal Patch Technology Viability to Address Underserved Lupus, Rheumatoid Arthritis and Malaria market, forecast to be worth $6 Billion USD by 2027*, Company to investigate Spin Out of Asset VANCOUVER, BC / ACCESSWIRE / April 1, 2021 / Codebase Ventures Inc. ("Codebase" or the "Company") (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is pleased to provide an update on the continued development of the Company's proposed transdermal delivery technology for hydroxychloroquine (HCQ), as first announced in April 2020. The C...